Conduit in to Phase II of Sarborg Collaboration to Support AI-Driven Drug Development

 

• Conduit and Sarborg complete all milestones of Phase I of their AI-driven drug development collaboration, and commence transitioning to Phase II, which will focus on developing personalized software dashboards to enhance efficiency, decision-making, and operational agility of its current and future portfolio
  

 Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), today announces the successful completion of all milestones in Phase I of its strategic collaboration with Sarborg Limited. This transition to Phase II marks a positive step forward in Conduit’s strategy to explore the integration advanced artificial intelligence (AI) and cybernetics into its drug development processes. With Phase I now complete, the Company is pleased to transition to Phase II, which will focus on the creation of personalized software dashboards to enhance operational efficiency and reporting.

https://www.globenewswire.com/news-release/2025/02/07/3022768/0/en/Conduit-Pharmaceuticals-Transitions-to-Phase-II-of-Sarborg-Collaboration-to-Support-AI-Driven-Drug-Development.html